3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing.
about
High Content Imaging (HCI) on Miniaturized Three-Dimensional (3D) Cell CulturesCutting-edge microfabricated biomedical tools for human pluripotent stem cell researchStem cell-derived liver cells for drug testing and disease modelingTranslational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug DiscoveryAdvances in Engineered Liver Models for Investigating Drug-Induced Liver InjuryInduced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous SystemDifferences in the Epigenetic Regulation of Cytochrome P450 Genes between Human Embryonic Stem Cell-Derived Hepatocytes and Primary HepatocytesReproducible Construction of Surface Tension-Mediated Honeycomb Concave Microwell Arrays for Engineering of 3D Microtissues with Minimal Cell LossMolecular mechanisms underlying the enhanced functions of three-dimensional hepatocyte aggregatesAggregate culture of human embryonic stem cell-derived hepatocytes in suspension are an improved in vitro model for drug metabolism and toxicity testing.Pregnane X receptor and drug-induced liver injury.HHEX promotes hepatic-lineage specification through the negative regulation of eomesodermin.Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine modelPrediction of Drug-Induced Liver Injury in Micropatterned Co-cultures Containing iPSC-Derived Human Hepatocytes.Engineering Strategies for the Formation of Embryoid Bodies from Human Pluripotent Stem Cells.Generation of enterocyte-like cells from human induced pluripotent stem cells for drug absorption and metabolism studies in human small intestineEngraftment of human induced pluripotent stem cell-derived hepatocytes in immunocompetent mice via 3D co-aggregation and encapsulation.Recombinant Laminins Drive the Differentiation and Self-Organization of hESC-Derived HepatocytesDeterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting.State-of-the-Art Metabolic Toxicity Screening and Pathway Evaluation.Enhanced hepatic differentiation of rat bone marrow-derived mesenchymal stem cells in spheroidal aggregate culture on a decellularized liver scaffold.Functional Maturation of Induced Pluripotent Stem Cell Hepatocytes in Extracellular Matrix-A Comparative Analysis of Bioartificial Liver Microenvironments.Cell sources for in vitro human liver cell culture models.Scalable Differentiation of Human iPSCs in a Multicellular Spheroid-based 3D Culture into Hepatocyte-like Cells through Direct Wnt/β-catenin Pathway Inhibition.Long-term self-renewal of human ES/iPS-derived hepatoblast-like cells on human laminin 111-coated dishes.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Engineering a perfusable 3D human liver platform from iPS cells.Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection.The future of the patient-specific Body-on-a-chip.Assembly of human organs from stem cells to study liver disease.Inducing pluripotency for disease modeling, drug development and craniofacial applications.Stem cell responses to nanotopography.Competency of different cell models to predict human hepatotoxic drugs.Bioartificial livers in vitro and in vivo: tailoring biocomponents to the expanding variety of applications.Application of biomaterials to advance induced pluripotent stem cell research and therapy.Bottom-Up Engineering of Well-Defined 3D Microtissues Using Microplatforms and Biomedical Applications.3D liver models on a microplatform: well-defined culture, engineering of liver tissue and liver-on-a-chip.Achilles' heel of pluripotent stem cells: genetic, genomic and epigenetic variations during prolonged culture.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.
P2860
Q26773298-C3154F0E-B993-4BE4-8966-B9D0915E3B45Q26827806-F45E2292-92E8-47B2-B70B-D55D409EBB71Q27012605-D1F5FEFC-D77B-482B-86BE-6263B1C897B9Q28072402-38CBCBC1-BC25-42A2-A5BD-4FF21B40B16EQ28077505-C5B117DF-912F-4151-A2C8-69DB1DFA4048Q28082668-FD430ACF-F04F-4BDD-81AA-7E024465E716Q28546589-DF1D09AF-D39D-4D12-AB25-CCE90C0C260CQ28553448-FE8EAB92-E666-42CE-BD3E-47BD06DB99FDQ33576077-136EC9EC-25B0-4918-9F9D-8FBD1ED554CBQ34048251-14978DB0-18E3-45ED-AA2C-5F3367C1658BQ34345049-D2F62E17-5E26-4D7C-B7A3-4EC98C30FF6CQ35126482-9C1D5DAC-D9FC-45C3-9E49-462A776A3F32Q35140067-DDC79F65-8105-4B12-88FD-D3441D5CDD94Q35567915-4F871C28-E6B8-4276-9BEC-523F3DC55DCFQ35844417-BB6E74CE-E1A8-45DF-91DB-6D20A101D247Q36272752-EF52A625-2B4D-4F96-806C-2093432A6DB3Q36305534-9325E4B1-234D-4448-97CD-138DBE369A27Q36379726-6D64E7DB-57CD-4CDD-8436-6FDA0F962F42Q36646507-C7AC92DE-D047-47AC-9548-2AEAFA02F51EQ36887497-A4B55CE4-9247-4131-AB05-C02871060A20Q37071699-694FB62D-F42A-43D2-B2DA-70979A218E4AQ37200883-0CDBD1EA-7503-4089-A733-33C498D212E2Q37208518-135A8D6D-7E3C-4567-AE74-6C94A29438F3Q37247461-28853E75-67E8-433A-A4E4-23EB5D4A2E20Q37360935-D4CF5AF8-72A3-49A1-8855-E80547918E36Q37590883-D87C08C1-F31B-450E-98F2-84627775A43DQ37655140-26B2E693-A394-4B78-9270-9AB95E524C71Q37718523-CA5B5A00-6DA1-43E5-A22B-197554EA54EEQ37736696-AF84F2F9-01BF-42CC-A885-713B5E97CDFEQ38107796-3E5414C6-C598-4DC3-BE89-331B5D9FA9F5Q38170868-4A573ECB-1A07-4E07-A425-B37173AD7614Q38213654-6E0CEF0E-E5CA-481D-92F8-ACC32174D1A7Q38213915-437B613A-0D22-497C-A050-9E61EDE7D670Q38258251-D8338D2C-2645-4A02-8342-00EF9CF14E61Q38264625-E171C34B-6797-4CC2-9244-6963F76BD608Q38376035-67768FA9-47FE-4C26-B4A6-3457A7618636Q38424004-AE337A7A-2235-436D-928F-AB8B546E23A2Q38567885-975DFA16-DFCC-4B3F-B879-AAC5A6A98FBCQ38767506-1BCF23B8-F5E2-462D-B47A-56C5C9F2C3E5Q38774776-DA1A87BF-48FA-467F-9593-F04347F76630
P2860
3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
3D spheroid culture of hESC/hi ...... lls for drug toxicity testing.
@en
3D spheroid culture of hESC/hi ...... lls for drug toxicity testing.
@nl
type
label
3D spheroid culture of hESC/hi ...... lls for drug toxicity testing.
@en
3D spheroid culture of hESC/hi ...... lls for drug toxicity testing.
@nl
prefLabel
3D spheroid culture of hESC/hi ...... lls for drug toxicity testing.
@en
3D spheroid culture of hESC/hi ...... lls for drug toxicity testing.
@nl
P2093
P1433
P1476
3D spheroid culture of hESC/hi ...... lls for drug toxicity testing.
@en
P2093
Fuminori Sakurai
Katsuhiro Kanda
Katsuhisa Tashiro
Kazuo Takayama
Keisuke Kishimoto
Kenji Kawabata
Masashi Tachibana
Miho Kusuda Furue
Takao Hayakawa
Yasuhito Nagamoto
P304
P356
10.1016/J.BIOMATERIALS.2012.11.029
P577
2012-12-08T00:00:00Z